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The Receptor Mechanisms Underlying the Disruptive Effects of Haloperidol and
Clozapine on Rat Maternal Behavior: A Double Dissociation between Dopamine
D2 and 5-HT2A/2C Receptors
Changjiu Zhao, Ming Li (mli2@unl.edu)

Department of Psychology, University of Nebraska–Lincoln, NE, USA
Abstract
Many antipsychotic drugs disrupt active components of maternal behavior such as pup approach, pup retrieval and nest building at clinically relevant doses in postpartum female rats. However, the neurochemical mechanisms underlying such a disruptive effect remain to be determined. This study examined the neurochemical mechanisms that mediate the disruptive effects
of haloperidol (a typical antipsychotic) and clozapine (an atypical antipsychotic) on rat maternal behavior. Postpartum rats
were administered with haloperidol (0.2 mg/kg, sc) or clozapine (10.0 mg/kg, sc) together with either vehicle (saline or water),
quinpirole (a selective dopamine D2/D3 agonist, 0.5 or 1.0 mg/kg, sc), or 2,5-dimethoxy-4-iodo-amphetamine (DOI, a selective 5-HT2A/2C agonist, 1.0 or 2.5 mg/kg, sc), and their maternal behaviors were tested at different time points before and after
drug administration. Haloperidol and clozapine treatment disrupted pup approach, pup retrieval, pup licking and nest building. Pretreatment of quinpirole, but not DOI, dose-dependently reversed the haloperidol-induced disruptions. In contrast, pretreatment of DOI, but not quinpirole, dose-dependently reversed the clozapine-induced disruptions. Quinpirole pretreatment
even exacerbated the clozapine-induced disruption of pup retrieval and nest building. These findings suggest a double dissociation mechanism underlying the disruption of haloperidol and clozapine on rat maternal behavior. Specifically, haloperidol
disrupts maternal behavior primarily by blocking dopamine D2 receptors, whereas clozapine exerts its disruptive effect primarily by blocking the 5-HT2A/2C receptors. Our findings also suggest that 5-HT receptors are involved in the mediation of rat
maternal behavior.
Received 6 April 6, 2009; received in revised form June 3, 2009; accepted June 10, 2009; available online June 17, 2009.
Keywords: Haloperidol; Clozapine; Dopamine D2/D3 receptor; Quinpirole; 5-HT2A/2C receptor; DOI; Rat maternal behavior.

1. Introduction
Maternal behavior in rats is a complex behavior that shares many
features with human mothering behavior (Fleming and Corter, 1988).
It is naturally expressed for the first time with the birth of the first
litter. Within hours of parturition, the mother rat reconstructs the
nest, retrieves the displaced pups, gathers them together in the nest
site and adopts a nursing posture over the pups to permit suckling
(Dollinger et al., 1980; Rosenblatt and Lehrman, 1963). The mother
rat (dam) continues to exhibit maternal behavior (pup licking, pup
retrieval, nest building and nursing) over the subsequent 3-week
period, although as the pups mature, the intensity and quality of her
behavior changes (Galef, 1981; Rosenblatt and Lehrman, 1963).
In recent years, we have used the rat maternal behavior as an ecologically relevant model to investigate the behavioral mechanisms of
action of antipsychotic drugs and attempted to capture the possible
side effects of antipsychotic medications on human parental behaviors. We and others have shown that clinically comparable doses
of haloperidol (HAL), clozapine (CLZ), risperidone and quetiapine
(~50%–70%, dopamine D2 occupancy) disrupt active components of
rat maternal behavior, such as pup retrieval, pup licking and nest

building (Li et al., 2004; Stern and Taylor, 1991; Stern and Keer, 1999;
Zhao and Li, 2009). HAL causes a prolonged disruption (up to 6 h),
whereas CLZ and other atypical antipsychotics induce an early onset
but transient disruption (less than 6 h). Novel antipsychotics such as
amisulpride and aripiprazole also exhibit a certain degree of inhibition on active maternal responses in a dose-dependent fashion (Li
et al., 2005a). Chronic treatment with HAL or olanzapine via minipumps or repeated daily injections significantly inhibits rat active
maternal responses as well (Li et al., 2005b). It seems that antipsychoticinduced inhibition on pup retrieval, pup licking and nest building may be an inherent feature of all currently available antipsychotics (Li et al., 2004, 2005a; Silva et al., 2001; Stern and Taylor, 1991;
Stern and Keer, 1999; Zhao and Li, 2009). Our recent work further
identifies that sedation and suppression of maternal motivation are
two important behavioral mechanisms underlying the disruptive
effects of antipsychotic treatment on maternal behavior (Zhao and
Li, 2009).
The present study investigated the neurochemical basis of antipsychotic-induced disruptive effects on rat maternal behavior. For typical antipsychotics, it is generally assumed that they disrupt maternal
behavior by blocking dopamine D2 receptors because they are pri-
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marily dopamine D2 antagonists (Dragunow et al., 1990; Seeman et
al., 1976), and because apomorphine, a dopamine receptor agonist,
can reverse the inhibitory effects of haloperidol (Giordano et al.,
1990). However, solid evidence demonstrating that typical antipsychotics do act through this specific D2 mechanism is still lacking.
For atypical antipsychotics (e.g., clozapine, olanzapine), because
they generally have multiple-receptor binding profiles (Meltzer,
1989; Miyamoto et al., 2005), it is hard to pinpoint their exact neurochemical mechanisms. Most atypical antipsychotics possess a
much more potent antagonism on the 5-HT2 receptor in addition to
relatively weak antagonism on D2 receptor (Meltzer et al., 2003). It
is thus possible that the disruptive effects of atypical antipsychotics on maternal behavior could be attributed to their action on D2
receptor alone (Kapur and Seeman, 2001) or to its dual action on
both 5-HT2 and D2 receptors (Meltzer et al., 1989a,b) or on other
receptors.
In the present study, we administered quinpirole, a selective D2/
D3 dopaminergic receptor agonist or 2,5-dimethoxy-4-iodo-amphetamine (DOI), a selective 5-HT2A/2C serotonergic receptor agonist
together with HAL (0.2mg/kg) or CLZ (10.0mg/kg) to postpartumrats.We examined which of these two agonists was able to reverse
the disruptive effects induced by HAL or CLZ. We hypothesized
that quinpirole, but not DOI, would be able to reverse the HALinduced disruption on maternal behavior and may also be effective
in alleviating the CLZ-induced disruption to some extent. We had
no prior conviction regarding the effect of DOI due to lack of sufficient evidence in the literature on the role of serotonin in maternal
behavior (Numan and Insel, 2003).
2. Materials and methods
2.1. Subjects
Animals were naive pregnant female Sprague–Dawley rats (9–12
weeks old at the start of pregnancy) purchased from Charles River
Inc. (Portage, MI). Upon arrival to our animal facility, the rats were
between gestational days 13–15. Each subject was housed individually in 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cage
lined with aspen shavings in a colony on a 12-h light/dark cycle
(lights on at 6:30 AM). All behavioral tests were performed in the
light phase between 9:00 AM and 4:00 PM. The colony was maintained under standard vivarium conditions with an ambient temperature of 23°C, relative humidity of 55–60%. Standard laboratory
rat chow and water were available ad libitum. All animal procedures
were approved by the University of Nebraska Institutional Animal
Care and Use Committee.
2.2. Drugs and choices of doses
HAL (5.0 mg/ml ampoules, Sicor Pharmaceuticals, Inc, Irvine,
CA) was diluted with sterile water. CLZ (a gift from NIMH drug
supply program) was dissolved in 1.0% glacial acetic acid in distilled water. Quinpirole (QUI) and DOI (RBI-Sigma, Natick, MA)
were dissolved in 0.9% saline. HAL (0.2 mg/kg), CLZ (10.0mg/kg),
QUI (0.5 or 1.0 mg/kg), DOI (1.0 or 2.5 mg/kg) and vehicle (water
or saline) were all administered subcutaneously in a volume of 1.0
ml/kg body weight. Choices of drug doses for HAL and CLZ were
based on our previous studies showing that, at these doses, HAL
and CLZ effectively disrupt active maternal behaviors in rats (Li et
al., 2004; Zhao and Li, 2009). The doses of QUI were chosen based
on our preliminary study showing that 1.0mg/kg of QUI improved
the HAL’s disruption on pup retrieval. DOI doses were chosen on
the basis of reports showing that DOI at these doses potentiates
the effects of amphetamine on dopamine release in the striatum,
medial prefrontal cortex and nucleus accumbens (Ichikawa andMeltzer, 1995; Kuroki et al., 2003) and blocks the CLZ-induced
dopamine release in the medial prefrontal cortex (Ichikawa et al.,
2001).
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2.3. Basic experimental procedure
Starting 2 or 3 days prior to the first possible expected parturition
date, the subjects were monitored every morning for signs of parturition. Once the dam was found with pups in the morning (that day
was designated as Day 1 postpartum), the mother was transferred
into a clean cage with wood shavings for bedding. Two shredded
paper towels were also provided for nesting material. The litter was
culled to 8 pups (4 males and 4 females with the most visible milk
bands). Maternal behavior tests were conducted on one day between
Days 6 and 8 postpartum.
2.4. Maternal behavior test
The basic procedure was similar to what has been described in
Zhao and Li (2009). Using a laptop computer with an event recording
program (JWatcher, http://www.jwatcher.ucla.edu/), we recorded
various components of maternal behavior in an 8-min testing session
at different time points before and after drug administration. Each
test started by removing the 8 pups from the dam and destroying the
nest. Ten seconds later, the pups were returned to the corner of the
cage diagonal to the nest site or dam sleeping corner. When the subject picked up a pup in her mouth and carried it back to the nest site,
it was referred to as a successful pup retrieval. The total number of
pups retrieved was recorded. Approach latency was defined as the
time taken for mother rats to approach and sniff the pups from the
reunion. First and last pup retrieval latency was defined as the time
elapsed from the first pup approach to the retrieval of the first and
eighth pup into the nest, respectively. A score of 480 s was assigned
to nonresponders who did not approach or retrieve the testing pups
at all.
The occurrence of other behaviors was also recorded, including
pup nursing behavior (a rat positioning herself over the pups with
legs splayed to accommodate the pups, including hover, high and
low crouching over postures), pup licking (a female rat placing its
tongue on the anogenital area and the rest of a pup’s body), nest
building (a rat picking up nesting material in her mouth and transporting it back to the nest site or pushing the material with her forepaws toward the nest site). At the conclusion of the test, any unretrieved pups were returned to the nest site.
2.4.1. Experiment 1. Effects of pretreatment with quinpirole or DOI on
haloperidol-induced maternal behavior deficits in rats
Forty-four postpartum rats were randomly assigned to one of
the following six groups: VEH+VEH (n=4, sterile water or saline),
VEH+HAL (n = 8), QUI-0.5+HAL (n = 8), QUI-1.0+HAL (n = 8), DOI1.0+HAL (n = 8), and DOI-2.5+HAL (n = 8). On the drug test day (1
day on either Postpartum Day 6, 7, or 8), all subjects were tested 5
times at different time points before and after drug administrations,
with the first maternal behavior test starting at 30 min prior to the
HAL or vehicle injection (i.e., baseline) and the other tests occurring at 30, 60, 120 and 240min after HAL or vehicle injection. QUI,
DOI or vehicle was injected s.c. twice with the first injection at 10
min before and the second at 50 min after the HAL or vehicle injection.We adopted such an injection strategy because our preliminary
data showed that injection of QUI at 10 min prior to the administration of HAL could optimally reverse its disruption on pup retrieval.
Also, agonists were injected twice separately on the basis of their relatively short duration of action and rapid peak plasma concentrations (Deutch and Duman, 1996; Whitaker and Lindstrom, 1987).
2.4.2. Experiment 2. Effects of pretreatment with quinpirole or DOI on clozapine-induced maternal behavior deficits in rats
The basic procedure was identical to that of Experiment 1 with the
exception that CLZ was tested in this experiment instead of haloperidol. Forty-four postpartum rats were randomly assigned to one
of the following six groups and their maternal behaviors were tested:
VEH+VEH (n = 4, sterile water or saline), VEH+CLZ (n = 8), QUI-0.5+
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CLZ (n = 8), QUI-1.0+CLZ (n = 8), DOI-1.0+CLZ (n = 8), and DOI2.5+CLZ (n = 8).
2.5. Data analysis
With the exception of latency data, various measurements of
maternal behavior were expressed as mean ± SEM. To increase statistical power, we combined the two vehicle control groups from
Experiments 1 and 2 into a single group since they did not differ significantly on any measure (Independent-Samples T test or Mann–
Whitney U test, all ps > 0.10). Data were analyzed using a factorial
repeated measures analysis of variance (ANOVA) with the betweensubjects factor being the treatment groups (e.g. saline, HAL) and the
within-subjects factor being test time points (baseline, 30, 60, 120
and 240 min post-injection). Group differences at different time
points were further analyzed using simple main effect test (one-way
ANOVA) followed by Turkey’s HSD post hoc tests where appropriate.
For the latency data, because they were not normally distributed
(e.g. the cut-off time assigned 480 s for the latency data), these data
were expressed as median ± interquartile range. Nonparametric
Kruskal–Wallis test was used for analyzing the differences among
the treatment groups. Once the overall significant effects were determined, two-group comparisons were performed using Mann–Whitney U test. A conventional two-tailed level of significance at the 0.05
level was required.
3. Results
3.1. Experiment 1. Effects of pretreatment with QUI or DOI on haloperidol-induced maternal behavior deficits
3.1.1. Haloperidol treatment disrupted various components of maternal
behavior
Consistent with our previous findings (Li et al., 2004; Zhao and
Li, 2009), a single injection of HAL significantly disrupted various
active components of maternal behavior (pup retrieval, pup licking, nest building, but not pup nursing). Rats treated with HAL took
a much longer time to initiate contact with pups and retrieve their
pups into the nest sites (Table 1) and retrieved fewer pups at the 30,
60, 120 and 240 min test points (Figures 1, 2A) (0.001 < all ps < 0.05)
compared to the vehicle-treated rats. They also spent less time licking their pups at the 30, 60 and 120 min test points and rebuilding
the nest at the 30, 60, 120 and 240 min test points (Figures 1, 2B, C)
(0.001 < all ps < 0.05). However, HAL treatment had no significant
effect on nursing activity (Figures 1, 2D).
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3.1.2. QUI pretreatment dose-dependently improved the haloperidolinduced maternal behavior deficits
As can be seen in Table 1 and Figure1A–C, both doses of QUI
improved the HAL-induced deficits in pup approach, pup retrieval,
pup licking and nest building, as described below.
3.1.2.1. Latency to approach and retrieve pups. QUI shortened the HALinduced increase in pup approach latency and the first and last pup
retrieval latencies (Table 1). Both 0.5 and 1.0 mg/kg doses of QUI
were effective in facilitating the HAL-treated dams to initiate contact
with their pups and completely restored such behavior to the normal
level (e.g., VEH+VEH group) across the testing period. For the pup
retrieval latency, it appeared that both doses of QUI shortened the
time the HAL-treated rats took to retrieve their first and last pups to
the nest site and reinstated the first pup retrieval to the normal level
at the 30, 120 and 240 min test points post-injection.
3.1.2.2. Number of pups retrieved. Both 0.5 and 1.0 mg/kg of QUI
increased the number of pups retrieved in the HAL-treated rats
and restored it to the normal level at certain time points of testing.
Repeated measures ANOVA revealed that there was a significant
interaction between the treatment groups and time points [F(20, 168)
= 5.97, p < 0.001], a significant main effect of treatment groups [F(5,
= 26.30, p < 0.001], and a significant effect of time points [F(4, 168)
42)
= 35.22, p < 0.001]. One-way ANOVA and post hoc tests showed
that the QUI-0.5+HAL group was significantly different from the
VEH+HAL group at the 30 and 120 min time points (Figure 1A, p <
0.001 for 30 min, p = 0.022 for 120 min), whereas the QUI-1.0+HAL
group differed from the VEH+HAL group at the 30, 120 and 240 min
test points (Figure 1A, p < 0.001 for 30 and 120 min, p = 0.014 for 240
min). Further analysis showed that the reversing effect of 0.5mg/
kg of QUI reached the control level at the 30 and 120 min test points
while the 1.0 mg/kg of QUI restored the CLZ-induced disruption
to the normal level at the 30, 120 and 240 min test pointswhen the
two QUI+HAL groupswere compared with the VEH+VEH control
group (Figure 1A, all ps > 0.10). It appears that the strongest reversal
effect of QUI occurred 120 min after HAL administration (Figure 1A).
3.1.2.3. Pup licking. QUI produced a reversing effect on HALinduced pup licking deficit. Repeated measures ANOVA revealed a
main effect of treatment groups [F(5, 42) = 4.56, p = 0.002], a significant
effect of test time points [F(4, 168) = 7.71, p < 0.001], but no significant
interaction between the two factors. One-way ANOVA and post hoc
tests showed that both QUI groups differed significantly fromthe
VEH+HAL group at the 120 min test point (Figure 1B, p = 0.045 for
QUI-0.5+HAL group, p = 0.042 for QUI-1.0+HAL group). Further
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6.18, p < 0.001], a significant main effect of treatment groups [F(5, 42) =
17.52, p < 0.001], and a significant effect of testing time [F(4, 168) = 35.95,
p < 0.001]. One-way ANOVA and post hoc tests showed that the
QUI-0.5+HAL group was significantly different from the VEH+HAL
group at the 120 and 240 min test points (both ps = 0.021), whereas
the QUI-1.0+HAL group differed significantly from the VEH+HAL
group at the 30, 120 and 240 min test points post-injection (Figure
1C, all ps < 0.001). In particular, although both doses of QUI reversed

analysis showed that the reversing effect reached the normal level
when the two QUI+HAL groups were compared to the VEH+VEH
control group (Figure1B, p = 0.85 for QUI-0.5+HAL group, p = 0.95
for QUI-1.0+HAL group).
3.1.2.4. Nest building. Similar to the effect on pup retrieval and pup
licking, both doses of QUI significantly improved the HAL-induced
disruption of nest building activity. Repeatedmeasures ANOVA
revealed a significant interaction between the two factors [F(20, 168) =

T he R eceptor M echanisms U nderlying

the

D isruptive E ffects

of

H aloperidol

the disruptive effect of HAL at the 120 min test point, only 1.0 mg/
kg of QUI was capable of improving it to the normal level when
compared to the VEH+VEH group (Figure 1C, p = 0.34).
3.1.2.5. Pup nursing. As can be seen in Figure1D,QUI pretreatment
had no significant effect on pup nursing. Repeatedmeasures ANOVA
revealed a significant interaction between the two factors [F(20, 168) =
2.14, p = 0.005], a significant main effect of treatment groups [F(5, 42) =
4.66, p = 0.002], and a significant effect of testing time [F(4, 168) = 10.53,
p < 0.001]. Post hoc tests showed that both QUI groups were not significantly different from the VEH+HAL group (both ps > 0.10).
3.1.3. DOI pretreatment failed to improve the haloperidol-induced maternal behavior deficits
Both 1.0 and 2.5 mg/kg of DOI failed to improve the HAL-induced
disruption on pup approach and pup retrieval, as evidenced by no
significant improvement in the approach latency nor in first and
last pup retrieval latency (Table 1) when the two DOI+HAL groups
were compared to the VEH+HAL group. Rather, 2.5 mg/kg of DOI
further exacerbated the HAL-induced disruption on the approach
latency at the 60 min test point (Table 1, p = 0.005). Post hoc tests
on the number of pups retrieved, pup licking and nest building
revealed that there was no significant difference between the two
DOI+HAL groups and the VEH+HAL group. For pup nursing, oneway ANOVA and post hoc tests indicated that the DOI-2.5+HAL
group showed an even more suppressed nursing duration at the 30
and 120 min test points compared to the VEH+HAL group (p = 0.048
for 30 min, p = 0.041 for 120 min) (Figure 2D). The DOI-1.0+HAL
group did not differ significantly from the VEH+HAL group across
the testing period.
3.2. Experiment 2. Effects of pretreatment with QUI or DOI on clozapineinduced maternal behavior deficits
3.2.1. Clozapine treatment impaired various components of maternal
behavior
Consistent with our previous findings (Li et al., 2004; Zhao and Li,
2009), the present study showed that a single injection of CLZ significantly disrupted various active components of maternal behavior and maintained such a disruptive effect for about 2 h. In comparison with the vehicle-treated ones, rats treated with CLZ took a
much longer time to approach and retrieve their first pups into the
nest sites (Table 2) at the 30, 60 and 120 min test points (0.001 < all
ps < 0.01) and took longer to bring the last pups into the nest with
less pups retrieved across the testing period (Table 2, Figures 3, 4A)
(0.001 < all ps < 0.05). They also spent less time on pup licking, nest
building and pup nursing at the 30, 60 and 120 min test points (Figures 3, 4B, C, D) (all ps < 0.05).

and

C lozapine

on

R at M aternal B ehavior 		

437

3.2.2. QUI pretreatment failed to improve the clozapine-induced maternal
behavior deficits
In contrast to its effects on HAL-induced maternal behavior deficits, both doses of QUI had little effect on the CLZ-induced disruptions of pup approach, pup retrieval latency (Table 2), the number of pups retrieved and nest building (Figure 3A,C). Contrarily,
QUI further potentiated the disruptive effect on these behaviors
(Table 2, Figure 3A,C). Repeated measures ANOVA on the number
of pups retrieved and nest building revealed a significant interaction between the treatment groups and test time points [the number of pups retrieved: F(20, 168) = 9.56, p < 0.001; nest building: F(20, 168)
= 2.77, p < 0.001], a significant main effect of treatment groups [the
number of pups retrieved: F(5, 42) = 20.41, p < 0.001; nest building:
F(5, 42) = 13.61, p < 0.001], and a significant effect of test time points
[the number of pups retrieved: F(4, 168) = 61.43, p < 0.001; nest building: F(4, 168) = 38.33, p < 0.001]. One-way ANOVA and post hoc tests
showed that the QUI-1.0+CLZ group differed significantly from the
VEH+CLZ group in the number of pups retrieved and the duration
of nest building at the 240 min test point (Figure 3A, C, p = 0.001 for
the number of pups retrieved, p = 0.007 for the nest building), while
the QUI-0.5+CLZ group differed from the VEH+CLZ group in nest
building at the 240 min test point (Figure 3C, p = 0.026). QUI pretreatment also did not improve the CLZ-induced deficits in pup licking
and pup nursing activities (Figure 3B,D) at any test points. Repeated
measures ANOVA on pup licking and pup nursing revealed a significant interaction between the two factors [pup licking: F(20, 168) =
1.68, p = 0.04; pup nursing: F(20, 168) = 2.05, p = 0.007], a significant main
effect of treatment groups [pup licking: F(5, 42) = 4.47, p = 0.002; pup
nursing: F(5, 42) = 5.52, p = 0.001], and a significant effect of test time
points [pup licking: F(4, 168) = 8.02, p < 0.001; pup nursing: F(4, 168) = 6.72,
p < 0.001]. Post hoc tests on pup licking and pup nursing revealed
that there was no significant difference between the two QUI+CLZ
groups and the VEH+CLZ group.
3.2.3. DOI pretreatment dose-dependently reversed the clozapine-induced
maternal behavior deficits
As shown in Table 2 and Figure 4A,B, pretreatment of both doses
of DOI (1.0 and 2.5 mg/kg) significantly improved the CLZ-induced
disruption on pup approach, pup retrieval, and pup licking. However, the reversing effect of DOI on CLZ-induced disruption of nest
building and pup nursing was not apparent (Figure 4C, D).
3.2.3.1. Latency to approach and retrieve pups. As shown in Table 2, both
1.0 and 2.5 mg/kg of DOI shortened the prolonged approach latency
induced by CLZ when the two DOI+CLZ groups were compared to
the VEH+CLZ group and restored it to the normal level compared
to the VEH+VEH group at the 30, 60 and 120 min test points (0.001 <
all ps < 0.01). It also reduced the CLZ-induced deficits of the first pup
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3.2.3.2. Number of pups retrieved. Both doses of DOI increased the number of pups retrieved in the CLZ-treated rats. One-way ANOVA and
post hoc tests showed that there was a significant difference between
the DOI-1.0+CLZ group and the VEH+CLZ group at the 60 and 120
min test points (p = 0.006 for 60 min, p = 0.008 for 120 min), whereas

retrieval and restored it to the normal level at the 60 min test point
(p = 0.035) at a dose of 1.0 mg/kg as well as at the 60 and 120 min
test points (both ps < 0.01) at a dose of 2.5 mg/kg. For the last pup
retrieval latency, both doses of DOI completely rescued the disruption at the 60 and 120 min (0.001 < all ps < 0.01) test points. Furthermore, 2.5 mg/kg of DOI shortened the last pup retrieval latency at
the 240 min test point (p = 0.001).
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the DOI-2.5+CLZ group differed significantly from the VEH+CLZ
group even at the 240 min test point (Figure 4A, 0.001 < all ps < 0.05).
Further analysis showed that the reversing effect of 1.0 mg/kg of
DOI reached the normal level at the 60 and 120 min test points while
the 2.5 mg/kg of DOI restored the CLZ-induced disruption to the
normal level at 60, 120 and 240 min test points (Figure 4A, all ps >
0.05). It appears that the strongest reversal effect of DOI occurred 120
min after CLZ administration (Figure 4A).
3.2.3.3. Pup licking. Both doses of DOI alleviated the CLZ-induced
disruption on pup licking. One-way ANOVA and post hoc tests
showed that there was a significant difference between the DOI1.0+CLZ group and the VEH+CLZ group at the 120 min test point
(p = 0.049), while the DOI-2.5+CLZ group differed significantly from
the VEH+CLZ group at the 60 and 120 min test points (Figure 4B, p =
0.034 for 60 min, p = 0.015 for 60 min). Further analysis showed that
only 2.5 mg/kg of DOI restored this behavior to the normal level
at the 60 and 120 min test points when the two DOI+CLZ groups
were compared with the VEH+VEH control group (Figure 4B, both
ps > 0.05).3.2.3.4. Nest building and pup nursing. Compared to the
reversing effects on pup retrieval and pup licking, DOI at the currently tested doses appeared to be ineffective in reversing the CLZinduced deficits on nest building and pup nursing. Post hoc tests on
nest building and pup nursing revealed that therewas no significant
difference between the two DOI+CLZ groups and the VEH+CLZ
group (Figure 4C, D, all ps > 0.05).
4. Discussion
The present study demonstrates an interesting double dissociation between dopamine and serotonin receptor mechanisms in the
mediation of HAL- and CLZ-induced maternal behavior deficits in
postpartum rats. Acute treatment of HAL and CLZ disrupted various components of rat maternal behavior. Pretreatment of QUI, a
selective D2/D3 dopaminergic receptor agonist, but not DOI, a selective 5-HT2A/2C serotonergic receptor agonist, dose-dependently
improved HAL-induced disruption of pup approach, pup retrieval,
pup licking and nest building, whereas pretreatment of DOI, but not
QUI, dose-dependently improved CLZ-induced disruptionof pup
approach, pup retrieval and pup licking. These data strongly suggest that the HAL-induced maternal deficits are primarily mediated by its blockade of D2 dopamine receptors, whereas the CLZinduced maternal deficits are primarily mediated by the blockade of
5-HT2A/2C receptors.
The dopamine systems have been well documented to play an
important role in the regulation of maternal behavior. For example, systemic (e.g., haloperidol, a D2 antagonist) or microinfusion
of dopamine receptor antagonists such as SCH-23390 (a D1 antagonist), pimozide (a D2 antagonist) and cis-flupenthixol (a mixed D1/
D2 antagonist) into the specific brain regions implicated in maternal
behavior (e.g., medial preoptic area, nucleus accumbens) disrupts
various active maternal behaviors (Byrnes et al., 2002; Giordano et
al., 1990; Keer and Stern, 1999; Li et al., 2004; Miller and Lonstein,
2005; Numan et al., 2005; Numan and Stolzenberg, 2009; Silva et al.,
2001, 2003; Stern and Taylor, 1991). 6-OHDA lesion of the ventral
striatum and ventral tegmental area disrupts pup retrieval (Hansen,
1994; Hansen et al., 1991a,b). Additionally, mother–pup separation,
which putatively enhances maternal motivation (Hansen, 1994),
stimulates dopamine release in the ventral striatum of maternal rats
(Hansen et al., 1993). Because HAL is primarily a D2 receptor antagonist, we hypothesized that it disrupts maternal behavior by blocking
D2 dopamine receptors. We tested this hypothesis by co-administrating QUI, a selective D2/D3 agonist together with HAL and examined
whether QUI could reverse the effects of HAL. As expected, QUI
did significantly improve the HAL-induced maternal behavior deficits. HAL rats pretreated with QUI showed shortened pup approach
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and retrieval latency than those pretreated with vehicle. This result
is in general agreement with a previous study showing that apomorphine, a mixed D1/D2 receptor agonist with a preferential affinity and potency for the D2 over D1 receptor subtype (Kebabian and
Calne, 1979), reversed HAL-induced pup retrieval deficits in postpartum rats (Giordano et al., 1990). We extended this line of research
by showing that HAL specifically acts on D2 receptors to achieve its
disruptive effect. Of note, this finding does not necessarily rule out
the involvement of the D1 receptor mechanism because HAL does
have a weak D1 antagonism (Miyamoto et al., 2005), and other studies also find that D1 receptors are involved in the regulation of maternal behavior (Miller and Lonstein, 2005; Numan et al., 2005; Numan
and Stolzenberg, 2009).
The lack of the effect of DOI treatment on HAL-induced maternal behavior deficits is not surprising given the fact that DOI is a
selective 5-HT2A/2C agonist and HAL lacks an action on these serotonergic receptor systems. Interestingly, DOI pretreatment further
decreased the duration of pup nursing in the HAL-treated rats (see
Figure 2D). Informal observations indicate that after the pups were
returned to the cage, the HAL rats pretreated with 2.5 mg/kg of DOI
did not approach and retrieve their pups, but stayed in the corner of
the cage with no apparent movement. This may explain the reduction of pup nursing by DOI. In light that DOI itself reduces locomotor activity (Hameleers et al., 2007; Krebs-Thomson and Geyer, 1996;
Mittman and Geyer, 1991; Wing et al., 1990), it is possible that DOIinduced hypolocomotor activity may have contributed to its disruptive effect on pup nursing.
Our original hypothesis that QUI may also attenuate the CLZinduced disruption to some extent, as CLZ also possesses a D2
antagonism, was not supported by the present findings. In contrast,
QUI actually worsened some maternal behavior deficits, such as on
pup retrieval and nest building. These findings indicate that CLZinduced maternal deficits are not primarily mediated by its weak
antagonism of D2 receptor. Our preliminary work (data not shown)
finds that QUI at a dose of 1.0 mg/kg by itself disrupts pup retrieval
and nest building. Therefore, it is possible that a combination of clozapine and QUI may provide an additive disruption on the CLZinduced maternal deficits.
The most striking finding from the present study was that DOI
pretreatment rescued most, if not all, maternal behavior deficits
induced by CLZ. We found that CLZ rats pretreated with DOI
took a much shorter time to initiate contact with pups and retrieve
their pups into the nest sites (Table 2), retrieved more pups (Figure 4A) and spent more time licking their pups than CLZ rats pretreated with vehicle (Figure 4B). CLZ has a unique and multifaceted
pharmacological, behavioral and clinical profile in comparison with
other antipsychotic drugs (Matsubara et al., 1993; Meltzer, 1989; Safferman et al., 1991; Schmauss et al., 1989) due to its multiple-receptor
action, including a relatively high affinity for D4, histaminergic (H1),
muscarinic, serotoninergic (5-HT2) and alpha-1-adrenergic receptors (Baldessarini et al., 1992; Lane et al., 1988; Meltzer, 1989; Meltzer et al., 1989a; Miller and Hiley, 1974; Seeman, 1992; Zavitsanou
et al., 2007), moderate affinity for D1, D2, D5, alpha-2-adrenergic and
5-HT3 receptors (Ellenbroek et al., 1991; Matsubara et al., 1993; Miyamoto et al., 2005; Murray and Waddington, 1990; Perry et al., 1983;
Remington and Kapur, 2000). The unique antipsychotic property of
CLZ (e.g., low EPS and less prolactin elevation) has been correlated
with its lowaffinity and fast dissociation at the D2 receptor (Kapur
and Remington, 2001; Kapur and Seeman, 2001; Seeman, 2002). This
profile makes it difficult to pinpoint the exact mechanisms mediating the antipsychotic and behavioral effects of CLZ. Our finding that
DOI dose-dependently improved the CLZ-induced maternal behavior deficits suggests that CLZ exerts its disruptive effect on maternal behavior through a 5-HT2A/2C receptor-mediated mechanism,
and that this effect thus might not be directly related to its antipsychotic efficacy, which is mediated by blockade of D2 receptors (Seeman, 2002).
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There are several possible mechanisms underlying the reversing effect of DOI on CLZ-induced maternal behavior deficits. First,
DOI may directly activate the 5-HT2A/2C receptors localized in the
brain regions important for maternal behavior, such as the nucleus
accumbens (NA) and the ventral tegmental area (VTA), etc. There
is considerable evidence demonstrating that moderate to high levels of 5-HT2A/2C receptor immunoreactivity (Bubar et al., 2005; Clemett et al., 2000; Cornea-Hébert et al., 1999; Jakab and Goldman-Rakic,
1998) and mRNAs (Eberle-Wang et al., 1997; Pompeiano et al., 1994;
Wright et al., 1995) are expressed in the NA and VTA, thus, DOI may
antagonize CLZ’s blockade on 5-HT2A/2C receptors through competitive binding to 5-HT receptors in these areas to alleviate the CLZinduced maternal behavior deficits.
Second, DOI may improve CLZ-induced maternal deficits through
its indirect action on the dopaminergic systems. The mesolimbic
dopamine system, originating in the VTA and terminating in the NA
has been implicated in the appetitive aspects of maternal behavior
(Hansen, 1994; Hansen et al., 1991a,b, 1993; Numan, 2007; Numan et
al., 2005). Recently, 5-HT2A/2C receptors were found to be localized on
the dopamine neurons in the VTA (Bubar and Cunningham, 2007;
Doherty and Pickel, 2000; Ji et al., 2006; Nocjar et al., 2002). This finding provides evidence in support of the possible interaction between
the serotonin and dopamine systems in the VTA (Alex and Pehek,
2007; Di Matteo et al., 2001). More importantly, a growing body of
evidence shows that 5-HT2 receptors play a prominent role in the
modulation of mesolimbic dopamine-mediated function. For example, in the NA, activation of 5-HT2 receptor appears to facilitate dopamine release that can be blocked by local injection of a 5-HT2 receptor antagonist (Parsons and Justice, 1993). DOI, a mixed 5-HT2A/2C
agonist, has been shown to increase extracellular levels of dopamine
in the posterior NA (Bowers et al., 2000). Thus, it is possible that DOI
may reverse the effect of CLZ by regulating the DA release in the
NA and thus indirectly regulatematernal behavior via the DA system. Future research should directly address the neural pathways
that mediate the modulatory effects of 5-HT2A/2C receptors on themesolimbic dopamine systems.
Third, at the behavioral level, the diminished sedation could be
a contributing factor in reversing CLZ-induced maternal deficits
by DOI. In the present study, we noted that DOI treatment significantly alleviated CLZ-induced sedative effect as those rats showed
increased motor activity, no sign of closed eyes or bowed head. It
has been reported that acute and repeated injection of CLZ at a dose
of 10.0 mg/kg produces substantial sedation in animals (Chesler
and Salamone, 1996). The CLZ-induced sedative effect has also
been reported in the clinic (Burke and Sebastian, 1993; Safferman
et al., 1991). Moreover, recent work from our laboratory shows that
the sedative effect of CLZ contributes to its disruption on maternal
behavior (Zhao and Li, 2009). At this point, it is still premature to
suggest that DOI reverses CLZ’s disruption on maternal behavior by
alleviating the sedative effect of CLZ, because CLZ is not known to
cause sedation by blocking 5-HT2A/2C receptors, but rather by blocking alpha-adrenergic and histamine receptors (Lieberman et al., 1989;
Safferman et al., 1991). More research is needed to examine whether
CLZ can cause sedation via action on 5-HT2A/2C receptors.
Because improvement of CLZ-induced disruption of nest rebuilding was not apparently observed after DOI pretreatment, it is possible that other neurotransmitter systems may be involved in CLZinduced nest building deficit. One such system could involve the
dopamine D2/D3 receptors, as our results show that HAL-induced
disruption of nest building was reversed and restored to the normal
level by QUI, a selective D2/D3 receptor agonist. Other systems may
include dopamine D1, D4 and D5 receptors. CLZ has high affinity for
D4 and moderate affinity for D1 and D5 receptors. Consistent with
this hypothesis, previous studies have shown that D1 receptor activity is critical for the regulation of maternal behavior. Microinjection
of a dopamine D1 receptor antagonist SCH-23390 into the medial
preoptic area (MPOA) or nucleus accumbens (NA) greatly impairs
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pup retrieval in postpartum rats (Miller and Lonstein, 2005; Numan
et al., 2005). Microinfusion of a dopamine D1 receptor agonist SKF38393 into either the MPOA or the NA promotes the onset of maternal behavior in pregnancy-terminated rats (Stolzenberg et al., 2007).
However, it is unknown whether the D4 and/or D5 receptors are
involved in the regulation of maternal behavior due to lack of evidence. Alternatively, nest building activity may still be mediated by
5-HT2A/2C receptors, but is more sensitive and vulnerable to pharmacological intervention (Li et al., 2004; Silva et al., 2001; Zhao and Li,
2009). Future work should address this issue in detail.
The present study provides strong evidence supporting the
involvement of 5-HT2A/2C receptors in the mediation of rat maternal
behavior. Previous work on this issue is inadequate and inconsistent. For example, Brunner et al. (1999) reported that 5-HT1B receptor
knockout mother mice did not display pup retrieval deficits. More
recently, Lerch-Haner et al. (2008) reported that transgenic mouse
dams with a specific disruption in serotonin neuron development
displayed profound maternal deficits (e.g., pup retrieval, pup nursing, nest building). This study, however, did not answer which subtypes of 5-HT receptor are implicated in maternal activity. Other
studies have found that 5-HT1B and 5-HT2A/2C receptors are involved
in maternal aggressive behavior (De Almeida et al., 2005, 2006a,b;
Olivier et al., 1995; Veiga et al., 2007). For example, intracerebroventricular injections of DOI, a 5-HT2A/2C agonist, inhibited maternal
aggression in postpartum female rats (De Almeida and Lucion,
1994). To the best of our knowledge, the present study was the first
to demonstrate that 5-HT2A/2C receptors may be important in regulating rat maternal behavior.
Consistent with our previous work (Li et al., 2004), we found that
HAL and CLZ had different time courses of action. HAL tended to
produce a prolonged disruption, whereas CLZ produced a transient one. For instance, the HAL-induced disruption of nest building was still apparent even at the 240 min test point (4 h post-injection), whereas the effect of CLZ was diminished (Figures 1, 3, C). It
appears that the reversal effect of QUI on HAL-induced maternal
deficits also differed in regard to time course of action from that of
DOI on CLZ-induced deficits. For example, the reversal effect of DOI
on CLZ-induced disruption of pup retrieval was somewhat delayed
in onset when compared to that of quinpirole on HAL-induced
impairment (Figures 1, 4A), which may be attributable to the rapid
peak plasma concentration of quinpirole (Whitaker and Lindstrom,
1987). Taken together, the present study demonstrates an interesting
double dissociation receptor mechanism underlying the HAL and
CLZ-induced maternal behavior deficits. Our data suggest that the
HAL-induced maternal deficits are primarily mediated by the blockade of D2 dopamine receptors, whereas the CLZ-induced maternal
deficits are primarily mediated by the blockade of 5-HT2A/2C receptors. Because not all components of CLZ-induced maternal behavior deficits were reversed by DOI, other receptor mechanisms such
as the D1 receptor may also be involved, prompting the need for further investigation.
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